Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06545500 | A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD | PHASE2 | COMPLETED | 46 | — | — | Aug 16, 2024 | Jan 8, 2025 | Feb 9, 2026 | 7 | United States |
| Arm | Type | Description |
|---|---|---|
| Dose Level A | EXPERIMENTAL | The treatment period will be 7 days, followed by a 7-day washout period, before beginning the next treatment in the sequence they were assigned to |
| Dose Level B | EXPERIMENTAL | The treatment period will be 7 days, followed by a 7-day washout period, before beginning the next treatment in the sequence they were assigned to |
| Dose Level C | EXPERIMENTAL | The treatment period will be 7 days, followed by a 7-day washout period, before beginning the next treatment in the sequence they were assigned to |
| Dose Level D | PLACEBO_COMPARATOR | The treatment period will be 7 days, followed by a 7-day washout period, before beginning the next treatment in the sequence they were assigned to |
| Name | Type | Description |
|---|---|---|
| Glycopyrrolate (85 μg) | DRUG | Administered by a standard jet nebulizer, twice daily for 7 consecutive days |
| Glycopyrrolate (42.5 μg) | DRUG | Administered by a standard jet nebulizer, twice daily for 7 consecutive days |
| Glycopyrrolate (14 μg) | DRUG | Administered by a standard jet nebulizer, twice daily for 7 consecutive days |
| Placebo | DRUG | Administered by a standard jet nebulizer, twice daily for 7 consecutive days |
Inclusion Criteria: * Males are eligible to participate if they agree to use contraception from Screening and throughout the study and for at least 30 days after the last dose of blinded study medication. * Females are eligible to participate if they are not pregnant, not breastfeeding, and ≥ 1 of ...